CNS erythroblastic sarcoma: a potential emerging pediatric tumor type characterized by NFIA::RUNX1T1/3 fusions.
CNS leukemia
Central nervous system
Myeloid sarcoma
NFIA::RUNX1T1
Journal
Acta neuropathologica communications
ISSN: 2051-5960
Titre abrégé: Acta Neuropathol Commun
Pays: England
ID NLM: 101610673
Informations de publication
Date de publication:
19 Jan 2024
19 Jan 2024
Historique:
received:
10
11
2023
accepted:
10
12
2023
medline:
20
1
2024
pubmed:
20
1
2024
entrez:
19
1
2024
Statut:
epublish
Résumé
Erythroblastic sarcoma (ES) (previously called chloroma or granulocytic sarcoma) are rare hematological neoplams characterized by the proliferation of myeloid blasts at extramedullary sites, and primarily involve the skin and soft tissue of middle-aged adults. ES may be concomitant with or secondary to myeloid neoplasms (mostly acute myeloid leukemia (AML)) or in isolated cases (de novo) without infiltration of the bone marrow by blasts. ES share cytogenetic and molecular abnormalities with AML, including RUNX1T1 fusions. Some of these alterations seem to be correlated with particular sites of involvement. Herein, we report an isolated erythroblastic sarcoma with NFIA::RUNX1T1 located in the central nervous system (CNS) of a 3-year-old boy. Recently, two pediatric cases of CNS MS with complete molecular characterization have been documented. Like the current case, they concerned infants (2 and 3 years-old) presenting a brain tumor (pineal involvement) with leptomeningeal dissemination. Both cases also harbored a NFIA::RUNX1T3 fusion. ES constitutes a diagnostic challenge for neuropathologists because it does not express differentiation markers such as CD45, and may express CD99 which could be confused with CNS Ewing sarcoma. CD43 is the earliest pan-hematopoietic marker and CD45 is not expressed by erythroid lineage cells. E-cadherin (also a marker of erythroid precursors) and CD117 (expressed on the surface of erythroid lineage cells) constitute other immunhistochemical hallmarks of ES. The prognosis of patients with ES is similar to that of other patients with AML but de novo forms seem to have a poorer prognosis, like the current case. To conclude, pediatric ES with NFIA::RUNX1T1/3 fusions seem to have a tropism for the CNS and thus constitute a potential pitfall for neuropathologists. Due to the absence of circulating blasts and a DNA-methylation signature, the diagnosis must currently be made by highlighting the translocation and expression of erythroid markers.
Identifiants
pubmed: 38243303
doi: 10.1186/s40478-023-01708-5
pii: 10.1186/s40478-023-01708-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
12Informations de copyright
© 2023. The Author(s).
Références
WHO Classification of Tumours Editorial Board (2022) Haematolymphoid Tumours. Lyon (France): International Agency for Research on Cancer. WHO classification of tumours series, 5th Edn. Vol. 11
Yang Y, Shu Y, Tang Y, Zhao S, Jia Y, Ji J et al (2023) RNA sequencing of myeloid sarcoma, shed light on myeloid sarcoma stratification. Cancer Med 12(8):9156–9166
doi: 10.1002/cam4.5654
pubmed: 36916780
pmcid: 10166975
Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJH, Pritchard DJ et al (2003) Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 348(8):694–701
doi: 10.1056/NEJMoa020890
pubmed: 12594313
Chisholm KM, Heerema-McKenney AE, Choi JK, Smith J, Ries RE, Hirsch BA et al (2020) Acute erythroid leukemia is enriched in NUP98 fusions: a report from the children’s oncology group. Blood Adv 4(23):6000–6008
doi: 10.1182/bloodadvances.2020002712
pubmed: 33284945
pmcid: 7724911
Linnik Y, Pastakia D, Dryden I, Head DR, Mason EF (2020) Primary central nervous system erythroid sarcoma with NFIA-CBFA2T3 translocation: a rare but distinct clinicopathologic entity. Am J Hematol 95(11):E299-301
doi: 10.1002/ajh.25944
pubmed: 32697373
Liu H, Guinipero TL, Schieffer KM, Carter C, Colace S, Leonard JR et al (2020) De novo primary central nervous system pure erythroid leukemia/sarcoma with t(1;16)(p31;q24) NFIA/CBFA2T3 translocation. Haematologica Avr 105(4):e194–e197
doi: 10.3324/haematol.2019.231928
King RL, Siaghani PJ, Wong K, Edlefsen K, Shane L, Howard MT et al (2021) Novel t(1;8)(p31.3;q21.3) NFIA-RUNX1T1 translocation in an infant erythroblastic sarcoma. Am J Clin Pathol 156(1):129–138
doi: 10.1093/ajcp/aqaa216
pubmed: 33313700
Vodyanik MA, Thomson JA, Leukosialin Slukvin II. (2006) (CD43) defines hematopoietic progenitors in human embryonic stem cell differentiation cultures. Blood 108(6):2095–2105
doi: 10.1182/blood-2006-02-003327
pubmed: 16757688
pmcid: 1895535
Ohgami RS, Chisholm KM, Ma L, Arber DA (2014) E-cadherin is a specific marker for erythroid differentiation and has utility, in combination with CD117 and CD34, for enumerating myeloblasts in hematopoietic neoplasms. Am J Clin Pathol Mai 141(5):656–664
doi: 10.1309/AJCP8M4QQTAZPGRP